ArticleSmart molecules : open access2026
Innovative 3D-bioprinted microfibers in calcium phosphate cement platform with Nell-1 to activate nerve-bone axis for synergistic bone, vasculature, and nanofibrous nerve regeneration.
Article in Smart molecules : open access, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Critical-sized bone defects remain a persistent clinical challenge, primarily because conventional scaffolds fail to reproduce the nanofibrous neurovascular architecture that underlies functional bone regeneration. Here, we present a breakthrough 3D-bioprinted platform combining alginate microfibers (aMF) laden with human periodontal ligament stem cells (hPDLSCs) and a calcium phosphate cement (CPC) matrix, creating a hybrid environment that bridges mechanical stability with nanofibrous neurovascular guidance. This platform is engineered for the spatiotemporal delivery of Nell-1, which uniquely activates a novel "nerve-bone" axis. Nell-1 engagement initiates a CYFIP1-mediated CGRP-β3 tubulin cascade that amplifies neurovascular and bone crosstalk. A dual-phase release profile emerges as a critical design feature, with early signaling creating a favorable microenvironment for neurovascular infiltration, and then sustain signaling over time. Together, these phases synergistically enhance osteogenesis by a 2-fold increase, angiogenesis by a 3-fold increase, and innervation by a 2-fold increase. When tested in rat cranial defects, our construct outperformed controls by doubling bone and nerve regeneration while tripling vascular density, thereby achieving unprecedented healing rates compared to existing approaches. Mechanistically, we redefine Nell-1 as a dual osteo-neurogenic regulator, leveraging endogenous stem cells to drive structural and functional repair. This 3D-bioprinted microfiber-in-CPC system advances beyond passive scaffolds by dynamically coupling structural support with bioactive signaling, offering a transformative strategy for neuro-vascularized bone reconstruction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.